Celladon Corp (CLDN)

19.77
0.50 2.59
NASDAQ : Health Care
Prev Close 19.27
Open 19.13
Day Low/High 19.00 / 19.89
52 Wk Low/High 12.90 / 28.35
Volume 22.76K
Avg Volume 10.50K
Exchange NASDAQ
Shares Outstanding 1.59M
Market Cap 27.50M
EPS -27.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
5 Stocks Moving on Unusual Volume

5 Stocks Moving on Unusual Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Celladon Announces Initiation Of Clinical Trial To Investigate MYDICAR In Patients With Heart Failure And A Left Ventricular Assist Device (LVAD)

Celladon Announces Initiation Of Clinical Trial To Investigate MYDICAR In Patients With Heart Failure And A Left Ventricular Assist Device (LVAD)

Proof of Concept Trial to Support Potential Future Utility of MYDICAR in LVAD Population

Celladon Reports Second Quarter 2014 Financial Results And Recent Highlights

Celladon Reports Second Quarter 2014 Financial Results And Recent Highlights

Conference Call Today at 8:30 a.m. Eastern Time

Celladon To Report Second Quarter 2014 Results On August 7, 2014

Celladon To Report Second Quarter 2014 Results On August 7, 2014

Investor Call Scheduled for 8:30am Eastern on Thursday, August 7, 2014

Celladon Corporation Announces In-License Of Stem Cell Factor Development Program

Celladon Corporation Announces In-License Of Stem Cell Factor Development Program

License Brings Novel Gene Therapy Approach for in situ Targeting of Multi-Potent Stem Cells for the Heart

4 Stocks Breaking Out on Big Volume

4 Stocks Breaking Out on Big Volume

These stocks rising on unusual volume are within range of triggering breakout trades.

Celladon Enters Oversold Territory (CLDN)

Celladon Enters Oversold Territory (CLDN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Celladon Reports First Quarter 2014 Financial Results And Recent Highlights

Celladon Reports First Quarter 2014 Financial Results And Recent Highlights

-- Conference Call Today at 4:30 p.m. Eastern Time --

Celladon To Host Investor And Analyst Day And Webcast On May 6th In New York City

Celladon To Host Investor And Analyst Day And Webcast On May 6th In New York City

--Dr. Roger J. Hajjar, Expert on SERCA2a in Heart Failure, Will Present--

Celladon Receives Breakthrough Therapy Designation From FDA For MYDICAR(R), Novel, First-in-Class Therapy In Development To Treat Heart Failure

Celladon Receives Breakthrough Therapy Designation From FDA For MYDICAR(R), Novel, First-in-Class Therapy In Development To Treat Heart Failure

MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation From FDA's Center for Biologics Evaluation and Research (CBER)

Celladon Reports Fourth Quarter And Year-End 2013 Financial Results And Recent Highlights

Celladon Reports Fourth Quarter And Year-End 2013 Financial Results And Recent Highlights

Conference Call Today at 4:30 p.m. Eastern Time

Celladon Completes Enrollment Of CUPID 2 Trial For Advanced Heart Failure

Celladon Completes Enrollment Of CUPID 2 Trial For Advanced Heart Failure

CUPID 2 Results Expected in April 2015

Celladon Announces Option Agreement With Servier

Celladon Announces Option Agreement With Servier

Servier Receives Exclusive Option to Enter Into Worldwide, Ex-U.S., Research Collaboration and License for Celladon's Novel Small Molecule SERCA2b Modulators for the Treatment of Diabetes and Metabolic Diseases

Celadon Group Inc. Q4 2010 Earnings Call Transcript

Celadon Group Inc. Q4 2010 Earnings Call Transcript

Celadon Group Inc. Q4 2010 Earnings Call Transcript